不同剂量米非司酮治疗子宫肌瘤的临床效果及安全性

Clinical efficacy and safety of different doses of mifepristone in the treatment of hysteromyoma

目的探究不同剂量米非司酮治疗子宫肌瘤的临床效果及安全性。方法选取2017年5月至2018年6月我院收治的72例子宫肌瘤患者为研究对象,将其随机分为对照组与试验组,每组36例。对照组采用25 mg/d米非司酮治疗,试验组采用12.5 mg/d米非司酮治疗。比较两组的治疗效果。结果试验组的治疗总有效率为97.22%,高于对照组的80.56%(P<0.05)。治疗后,两组子宫及子宫肌瘤体积均明显缩小,且试验组小于对照组(P<0.05)。治疗后,两组患者临床症状评分均降低,且试验组低于对照组(P<0.05)。试验组不良反应总发生率为8.33%,低于对照组的38.89%(P<0.05)。结论 12.5 mg/d米非司酮治疗子宫肌瘤的临床效果要优于25 mg/d,且其在治疗中不良反应总发生率更小,安全性更高,更值得临床推广应用。

Objective To explore the clinical efficacy and safety of different doses of mifepristone in the treatment of hysteromyoma.Methods A total of 72 patients with hysteromyoma admitted in our hospital from May 2017 to June 2018 were selected as study objects and randomly divided into control group and experimental group,with 36 cases in each group.The control group was treated with 25 mg/d mifepristone,and the experimental group was treated with 12.5 mg/d mifepristone.The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the experimental group was 97.22%,which was higher than 80.56% in the control group (P<0.05).After treatment,the volume of uterus and hysteromyoma in both groups decreased significantly,and those in the experimental group were smaller than the control group (P<0.05).After treatment,the scores of clinical symptoms in both groups decreased,and those in the experimental group were lower than the control group (P<0.05).The total incidence of adverse reactions in the experimental group was 8.33%,which was lower than 38.89% in the control group (P<0.05).Conclusion The 12.5 mg/d mifepristone is more effective than 25 mg/d in the treatment of hysteromyoma,and has less adverse reactions and higher safety,which is more worthy of clinical promotion and application.